Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors
A Study for Patients with Advanced Solid Tumors Using Study Drug BMS-986207
Sponsor: Bristol-Myers Squibb
Enrolling: Male and Female Patients
IRB Number: AAAR0263
U.S. Govt. ID: NCT02913313
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of the study is to test the safety of an investigational/study drug called BMS-986207 (also known as Anti TIGIT monoclonal antibody) administered alone and in combination with nivolumab. This study will investigate how research subjects/participants with advanced solid tumors tolerate these drugs and identify the highest dose or most suitable dose, of BMS-986207 alone and in combination with nivolumab, in cancer research subjects/participants. This is the first study in which BMS-986207 will be administered to humans. Nivolumab has been administered to and is approved for human use in multiple tumor types. Cancers include Colon cancer, rectal cancer, ovarian cancer, liver cancer, and lung cancer.
Investigator
Shaheer Khan, DO
Do You Qualify?
Are you over the age of 18? Yes No
Have you been diagnosed with an advanced solid tumor? Yes No
Are you able to walk, care for yourself, and do light house or office work? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162